The antibody contract manufacturing market is projected to grow at an annualized rate of 12%, till 2030

Author : kevin987
Publish Date : 2021-02-16 12:05:42


Roots Analysis has done a detailed study on Antibody Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link

 

Key Market Insights

  • Several companies worldwide claim to possess the required expertise and infrastructure to offer contract manufacturing services for a variety of antibody-based products.
  • The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of antibody CMOs claim to operate as one stop shops and have presence across different regions.
  • In recent years, a steady increase in partnership activity has been observed in this domain; a variety of deals have been inked related to antibodies for use across a number of different disease indications.
  • At present, the installed, global antibody contract manufacturing capacity is estimated to be approximately 2.2 million liters, distributed across companies of all sizes worldwide.
  • In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities.
  • In fact, ongoing capability improvement efforts and facility upgrades have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives in this domain.
  • Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade.
  • Antibody-based product developers are likely to continue to outsource their manufacturing operations in mid to long term, resulting in a multi-billion growth opportunity for contract service providers.

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

 

Table of Contents

 

1.         PREFACE

1.1.       Scope of the Report

1.2.       Research Methodology

1.3.       Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.       Chapter Overview

3.2.       Concept of an Antibody

3.3.       Structure of an Antibody

3.4.       Antibody Isotypes

3.5.       Mechanism of Action of Antibodies

 

3.6.       Types of Antibodies

3.6.1.    Monoclonal Antibodies

3.6.2.    Bispecific Antibodies

3.6.3.    Polyclonal Antibodies

 

3.7.       Overview of Contract Manufacturing

3.8.       Need for Outsourcing in the Biopharmaceutical Industry

3.9.       Advantages of Outsourcing Manufacturing Services

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview 

4.2.       Antibody Contract Manufacturers: Overall Market Landscape

4.2.1.    Analysis by Year of Establishment 

4.2.2.    Analysis by Number of Employees 

4.2.3.    Analysis by Scale of Operation 

4.2.4.    Analysis by Location of Headquarters

4.2.5.    Analysis by Location of Antibody Manufacturing Facilities

4.2.6.    Analysis by Type of Antibodies Manufactured 

4.2.7.    Analysis by Expression Systems Used

4.2.8.    Analysis by Regulatory Accreditations / Certifications

4.2.9.    Additional Services Offered

 

5.         COMPANY COMPETITIVE ANALYSIS

5.1.       Chapter Overview

5.2.       Assumptions and Key Input Parameters

5.3.       Methodology

5.4.       Company Competitiveness Analysis: Antibody Contract Manufacturers in North America

5.5.       Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe

5.6.       Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       AGC Biologics

6.2.1.    Company Overview

6.2.2.    Service Portfolio

6.2.3.    Manufacturing Facilities and Capabilities

6.2.4.    Future Outlook

 

6.3.       Aldevron

6.3.1.    Company Overview

6.3.2.    Service Portfolio

6.3.3.    Manufacturing Facilities and Capabilities

6.3.4.    Future Outlook

 

6.4.       AMRI

6.4.1.    Company Overview

6.4.2.    Service Portfolio

6.4.3.    Manufacturing Facilities and Capabilities

6.4.4.    Future Outlook

 

6.5.       BioXcellence (Boehringer Ingelheim)

6.5.1.    Company Overview

6.5.2.    Service Portfolio

6.5.3.    Manufacturing Facilities and Capabilities

6.5.4.    Future Outlook

 

6.6.       Emergent BioSolutions

6.6.1.    Company Overview

6.6.2.    Service Portfolio

6.6.3.    Manufacturing Facilities and Capabilities

6.6.4.    Future Outlook

 

6.7.       Eurofins CDMO

6.7.1.    Company Overview

6.7.2.    Service Portfolio

6.7.3.    Manufacturing Facilities and Capabilities

6.7.4.    Future Outlook

 

6.8.       FUJIFILM Diosynth Biotechnologies

6.8.1.    Company Overview

6.8.2.    Service Portfolio

6.8.3.    Manufacturing Facilities and Capabilities

6.8.4.    Future Outlook

 

6.9.       KBI Biopharma

6.9.1.    Company Overview

6.9.2.    Service Portfolio

6.9.3.    Manufacturing Facilities and Capabilities

6.9.4.    Future Outlook

 

6.10.     Lonza

6.10.1.  Company Overview

6.10.2.  Service Portfolio

6.10.3.  Manufacturing Facilities and Capabilities

6.10.4.  Future Outlook

 

 

6.11.     Nitto Avecia Pharma Services

6.11.1.  Company Overview

6.11.2.  Service Portfolio

6.11.3.  Manufacturing Facilities and Capabilities

6.11.4.  Future Outlook

 

6.12.     Novasep

6.12.1.  Company Overview

6.12.2.  Service Portfolio

6.12.3.  Manufacturing Facilities and Capabilities

6.12.4.  Future Outlook

 

6.13.     Pierre Fabre

6.13.1.  Company Overview

6.13.2.  Service Portfolio

6.13.3.  Manufacturing Facilities and Capabilities

6.13.4.  Future Outlook

 

6.14.     Samsung BioLogics

6.14.1.  Company Overview

6.14.2.  Service Portfolio

6.14.3.  Manufacturing Facilities and Capabilities

6.14.4.  Future Outlook

 

6.15.     Synthon

6.15.1.  Company Overview

6.15.2.  Service Portfolio

6.15.3.  Manufacturing Facilities and Capabilities

6.15.4.  Future Outlook

 

6.16.     Thermo Fisher Scientific

6.16.1.  Company Overview

6.16.2.  Service Portfolio

6.16.3.  Manufacturing Facilities and Capabilities

6.16.4.  Future Outlook

 

7.         CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

7.1.       Chapter Overview

7.2.       Small Molecule Drugs and Biologics

7.2.1.    Comparison of Strengths and Weakness of Small Molecules and Biologics

7.2.2.    Comparison of Key Specifications

7.2.3.    Comparison of Manufacturing Processes

7.2.4.    Comparison of Key Manufacturing related Challenges

 

8.         BENCHMARK ANALYSIS

8.1.       Chapter Overview

8.2.       Methodology

8.3.       Region-wise Benchmarking

8.3.1.    North America, Peer Group I

8.3.2.    North America, Peer Group II

8.3.3.    North America, Peer Group III

8.3.4.    Europe, Peer Group IV

8.3.5.    Europe, Peer Group V

8.3.6.    Europe, Peer Group VI

8.3.7.    Asia, Peer Group VII

8.3.8.    Asia, Peer Group VIII

 

8.4.       Concluding Remarks

 

9.         PARTNERSHIPS

9.1.       Chapter Overview

9.2.       Partnerships Models

 

9.3.       Antibody Contract Manufacturing: List of Partnerships

9.3.1.    Analysis by Year of Partnership

9.3.2.    Analysis by Type of Partnership

9.3.3.    Analysis by Year and Type of Partnership

9.3.4.    Analysis



Catagory :general